

2 December, 2025.

I-SCREEN APPOINTS CHIEF EXECUTIVE OFFICER FOR REGIONAL EXPANSION

Perth, Western Australia — 2 December, 2025: i-screen, Australia's leading clinical biomarker testing and bioinformatics platform, today announced the appointment of Scott Montgomery as Group Chief Executive Officer, signaling a strengthened commitment to expand its footprint across Australia, New Zealand, the United Kingdom, and into Asia.

Founded in 2015 by Amelia Thornycroft, a former partner at technology consulting firm Accenture, i-screen has grown into the region's most trusted provider of clinical-grade blood pathology, microbiome, genetic and imaging-based health screening services. The company now serves well over 100,000 unique users and supports a network of more than 3,500 health practitioners, establishing itself as the largest private B2C pathology platform in Australia. i-screen also supports operations in New Zealand and the United Kingdom.

Montgomery brings extensive leadership experience across public and private health technology companies operating throughout APAC, UK and North America. He holds a proven track record in scaling digital health and enterprise healthcare platforms, his appointment marks an important evolution for i-screen as the company accelerates innovation and prepares for broader expansion into Asian markets.

"i-screen has achieved impressive growth by delivering secure, clinical health tests with a relentless focus on service quality and user value," Montgomery said.

"With the rise of health optimisation, preventative care and longevity medicine, i-screen is uniquely positioned as the region's most proven biomarker testing platform. I'm excited to lead the next chapter with Amelia and the team as we expand across APAC and the UK."

Founder Amelia Thornycroft welcomed the appointment:

"Scott brings deep experience across global health-tech markets, including public companies in Australia, Canada and the USA. His capability in driving operational scale, digital transformation and clinical partnerships aligns perfectly with i-screen's mission. We are delighted to have him join as Group CEO."

i-screen's platform provides secure, evidence-based testing across blood pathology, microbiome, genetics, and imaging, supported by an advanced digital interface designed for both consumers and healthcare practitioners. The company's continued investment in scientific innovation and data-driven care pathways supports the growing demand for personalised health, longevity, and preventative care solutions.

As part of its strategic roadmap, i-screen is expanding its operational presence from Australia, New Zealand, and the United Kingdom, into Asia with further international developments to be announced in early 2026.

Organisations across APAC and the UK seeking clinical-grade biomarker solutions for their members, patients or policyholders can learn more at:

www.i-screen.com.au

www.i-screen.co.nz

www.healthily.co.uk

About i-screen.

i-screen is a clinical biomarker testing and bioinformatics platform providing secure, evidence-based screening from accredited blood pathology, microbiome and genetics laboratories and imaging clinics. Founded in 2015 in Western Australia, i-screen empowers individuals and healthcare practitioners with clear, actionable insights through an intuitive digital platform. With more than 100,000 users and over 3,500 practitioner partners, i-screen is Australia's largest private provider of direct-to-consumer pathology testing and a rapidly expanding leader across APAC and UK.

Media Contact.

Email: admin@i-screen.com.au

Website: www.i-screen.com.au